Compare OLED & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | DNTH |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | 469 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.5B |
| IPO Year | 1996 | 2018 |
| Metric | OLED | DNTH |
|---|---|---|
| Price | $78.06 | $93.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $125.00 | $121.00 |
| AVG Volume (30 Days) | 713.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 9.25 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $650,611,000.00 | $2,036,000.00 |
| Revenue This Year | $5.88 | N/A |
| Revenue Next Year | $10.36 | $29.48 |
| P/E Ratio | $103.61 | ★ N/A |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $77.15 | $18.08 |
| 52 Week High | $161.92 | $98.70 |
| Indicator | OLED | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 58.81 |
| Support Level | N/A | $79.27 |
| Resistance Level | $96.40 | $96.50 |
| Average True Range (ATR) | 4.02 | 5.26 |
| MACD | -0.70 | 1.20 |
| Stochastic Oscillator | 9.14 | 79.76 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.